SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-049328
Filing Date
2019-09-09
Accepted
2019-09-09 16:41:28
Documents
4
Period of Report
2019-09-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a19-18422_18k.htm 8-K 25929
2 EX-99.1 a19-18422_1ex99d1.htm EX-99.1 41234
3 EX-99.2 a19-18422_1ex99d2.htm EX-99.2 10986
4 GRAPHIC g184221moi001.jpg GRAPHIC 3346
  Complete submission text file 0001104659-19-049328.txt   84096
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 191083477
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1